Valuation of novel formulation of insulin for diabetes

Challenge A preclinical stage biotech company developing a novel formulation of insulin to treat diabetes mellitus was in discussions with prospective investors for a next round of funding. To...
Learn More

Valuation of a portfolio of therapeutics for an investment firm

Challenge An investment firm required independent valuations of five therapeutics within two of its portfolio companies, including four preclinical programs and a proprietary formulation of a...
Learn More

Valuation of a small molecule therapeutic for enhanced male infertility

Challenge A biotech company had developed preclinical data supporting the use of its lead drug candidate in enhancing male fertility. The product was being considered for both ex-vivo usage prior to...
Learn More

Oncology clinical expert input and asset valuation

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...
Learn More

Preclinical & clinical asset pipeline valuation

Challenge: A young biotech company with a portfolio of clinical and pre-clinical stage bispecific antibodies (BsAb) to treat various cancers was in the process of completing a Series A funding round....
Learn More

Presenting technology & clinical programs at ASH & SABCS

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its technology and...
Learn More

Asset scouting for in-licensing opportunities in fibrosis

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets....
Learn More

Distressed company analysis for asset scouting

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company wanted to...
Learn More

Scouting in-licensing opportunities for a mid-size pharma company

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...
Learn More

Valuation of a repurposed, male-fertility drug using Monte Carlo

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal negotiations. The...
Learn More

Clinical, CMC regulatory & CMC manufacturing due diligence

Challenge: An east coast biotechnology company had reached non-binding terms with an overseas company for development and commercialization rights to a novel anti-cancer product with a...
Learn More

Due diligence & product development planning of a collaboration

Challenge: A well-capitalized US biotechnology company was considering entry into the CAR-T space through a license and research collaboration with a leading US university with a distinguished and...
Learn More